Distributor inventory | Tablet
Glimepiride 3 mg + Voglibose 0.3 mg tablet
Type 2 diabetes mellitus to improve blood glucose control when diet and exercise alone are not adequate; may be used when dual therapy is required for post‑meal and fasting glucose control.
Glimepiride (a sulfonylurea) increases insulin release from the pancreas and improves insulin sensitivity. Voglibose (an alpha‑glucosidase inhibitor) delays intestinal carbohydrate digestion and absorption, reducing post‑meal blood sugar spikes.
Take orally as prescribed by the doctor, usually once daily with the first main meal (or just before meals as advised). Swallow whole with water; do not skip meals after taking it. Monitor blood glucose regularly.
Common side effects of GLYNAMIC-MV 3/0.3MG TAB may include:
Risk of low blood sugar—more likely with missed meals, alcohol, strenuous exercise, or with other antidiabetics; carry glucose. Use with caution in kidney or liver impairment and in elderly patients. Not recommended in type 1 diabetes or diabetic ketoacidosis. Seek medical help for severe abdominal pain, jaundice, or allergic reactions. Regular monitoring of blood glucose, HbA1c, and liver function may be advised.
